Anokion
Latest round
- Series B
Last raised
- Sep 2019
Total raised
- $77M
Investors
- 4
About Anokion
Founded in 2010, Anokion SA is based in Ecublens, Switzerland. The company specializes in immune tolerance therapies and has undergone development to streamline its therapeutic offerings. The current CEO is Deb Geraghty, and the company was founded by Stephan Kontos.Anokion specializes in innovative immune tolerance therapies aimed at treating autoimmune diseases. The company's core product offerings are centered around its proprietary immune tolerance platform, which utilizes engineered proteins, or antigens, to deliver precise and targeted therapies that minimize the side effects associated with traditional broad immunosuppressive treatments. This platform has a wide potential application across various clinical uses, addressing conditions such as celiac disease and multiple sclerosis. Anokion's target clientele includes healthcare providers, research institutions, and pharmaceutical partners within the biopharmaceutical industry, primarily focusing on markets in North America and Europe.Anokion’s revenue model is structured around partnerships with biopharmaceutical companies and healthcare providers for the development and commercialization of its immune tolerance therapies. Transactions typically occur through collaborative agreements that may involve milestone payments and royalties tied to successful clinical outcomes. The company’s flagship products, such as those targeting celiac disease and multiple sclerosis, are developed under these partnership frameworks, facilitating both B2B transactions with pharmaceutical partners and potential licensing agreements. The company aims to expand its product offerings and enhance therapeutic developments in the autoimmune disease space. Anokion is also focusing on broadening its market presence in North America and Europe, seeking to reach more healthcare providers and institutions by 2024.
Who invested in Anokion
4 investors across 2 rounds
See all investors in Anokion
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Anokion
Who invested in Anokion?
Anokion has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Anokion raised?
Anokion has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Anokion last raise money?
Anokion's most recent round on record is a Series B, in Sep 2019.
What does Anokion do?
Founded in 2010, Anokion SA is based in Ecublens, Switzerland.
Where is Anokion headquartered?
Anokion is headquartered in Ecublens, Switzerland.
Which VCs invest in companies like Anokion?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Anokion's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Anokion? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.